| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| ISIN code | US4364401012 |
| Industry group | Health Care Equipment & Services |
| Aligned with SDGs |
Founded in 1985, Hologic develops, manufactures, and supplies premium diagnostics products, medical imaging systems, and surgical products focused on women's health and wellbeing through early detection and treatment. The company operates in four product segments: Diagnostics (screening and diagnosis of human diseases), Breast Health (solutions for breast cancer care for radiology, pathology, and surgery), GYN Surgical (devices for the treatment of abnormal uterine bleeding, incision-less removal of fibroids, polyps, and other pathology within the uterus), and Skeletal Health (devices to evaluate bone density and perform body composition assessments). Hologic serves healthcare providers globally and is recognized for its leadership in women’s health innovation.
Investment rationale
The World Health Organization (WHO) identifies sexually transmitted infections (STIs) and breast cancer as health issues with profound impact worldwide, particularly in low- and middle-income countries where diagnostic tests are often unavailable. Even in higher-income countries, testing can be expensive, geographically inaccessible, and result in long wait times for results, impeding follow-up care and treatment. Breast cancer is the most common cancer among women globally, with incidence rising in developing regions due to increased life expectancy, urbanization, and adoption of western lifestyles. Early detection is crucial for improving outcomes and survival rates.
Hologic’s products focus on women’s health and are vital in diagnosing and managing diseases such as STIs and breast cancer. The company has initiatives to improve accessibility, including offering its products at reduced prices in resource-limited countries. Hologic developed the Global Women’s Health Index to track women’s health over time, aiming to improve equity and expand access to life-saving medical treatments worldwide. Hologic also contributes to child welfare directly, through tests for pre-term birth risk, and indirectly, as maternal health directly affects children’s wellbeing.
Alignment with Triodos Transitions:
100% of the company's revenues is aligned with the Wellbeing Transition. The contribution to the Wellbeing Transition comes from 100% of revenues related to the impact objective Health Care.